CN-121971439-A - Application of biotin in preparation of medicine for treating or preventing ischemia reperfusion injury

Abstract

The invention discloses application of biotin in preparing a medicament for treating or preventing ischemia reperfusion injury, which is applied to intervention research of ischemia reperfusion injury for the first time, and a system verifies the protection effect of the biotin in a cell inflammation model and an animal ischemia reperfusion model, lays a solid experimental foundation for application of the biotin in treatment of related diseases such as pulmonary ischemia reperfusion injury, ischemia reperfusion induced pulmonary arterial hypertension and the like, and provides a brand-new intervention strategy.

Inventors

• LIU HAIPENG
• Zheng Mengge
• GAO PEIGEN

Assignees

• 上海市肺科医院（上海市职业病防治院）

Dates

Publication Date

20260505

Application Date

20260311

Claims (6)

1. 1. Use of biotin in the manufacture of a medicament for the treatment or prevention of ischemia reperfusion injury.
2. 2. The use according to claim 1, wherein the ischemia reperfusion injury is a pulmonary ischemia reperfusion injury.
3. 3. The use according to claim 2, wherein the ischemia reperfusion injury is ischemia reperfusion-induced pulmonary hypertension.
4. 4. The use according to claim 1, wherein the route of administration of the medicament is intraperitoneal injection.
5. 5. The use according to claim 4, wherein the medicament is administered in a dose of 5-10mg/kg body weight.
6. 6. The use according to claim 1, wherein the medicament further comprises pharmaceutically acceptable excipients.

Description

Application of biotin in preparation of medicine for treating or preventing ischemia reperfusion injury Technical Field The invention relates to the technical field of biological medicine, in particular to application of biotin in preparing a medicament for treating or preventing ischemia reperfusion injury. Background Ischemia reperfusion injury (Ischemia-reperfusion injury, IRI) refers to secondary injury induced when blood perfusion is restored after tissue ischemia, and is a common and key pathological link of various major diseases such as cardiac surgery, organ transplantation, acute myocardial infarction, cerebral apoplexy, traumatic shock and the like. IRI is not only prevalent but also severe, directly aggravates tissue injury, promotes multi-organ dysfunction, and remarkably increases the death rate and medical burden of related diseases. The essence of IRI is secondary injury induced upon restoration of blood flow following tissue ischemia, whose core mechanisms involve oxidative stress bursts, excessive inflammatory responses, and various forms of cell death. Accordingly, the key principle of alleviating ischemia reperfusion injury is to inhibit the above-mentioned pathogenic links, namely control oxidative damage, block inflammatory cascade, reduce apoptosis and other death processes, and promote endogenous repair mechanisms. At present, the intervention measures aiming at IRI clinically are mainly focused on application of ischemia pretreatment, mechanical perfusion and antioxidants, but have the limitations of complex operation, limited applicable population, inaccurate curative effect and the like. Disclosure of Invention The invention aims at overcoming the defects in the prior art and provides the application of biotin in preparing a medicament for treating or preventing ischemia reperfusion injury. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: there is provided the use of biotin in the manufacture of a medicament for the treatment or prevention of ischemia reperfusion injury. Further, the ischemia reperfusion injury is a lung ischemia reperfusion injury. Still further, the ischemia reperfusion injury is ischemia reperfusion-induced pulmonary hypertension. Further, the administration route of the drug is intraperitoneal injection. Further, the drug is administered at a dose of 5-10mg/kg body weight. Further, the medicament also comprises pharmaceutically acceptable auxiliary materials. Compared with the prior art, the invention has the following technical effects: The invention applies biotin to the intervention research of ischemia reperfusion injury for the first time, the system verifies the protection effect of the biotin in a cell inflammation model and an animal ischemia reperfusion model, lays a solid experimental foundation for the application of the biotin in the treatment of related diseases such as pulmonary ischemia reperfusion injury, ischemia reperfusion induced pulmonary arterial hypertension and the like, and provides a brand-new intervention strategy. Drawings FIG. 1A shows the effect of different concentrations of biotin on the expression of macrophage TNF- α mRNA under LPS stimulation, and FIG. 1B shows the effect of different concentrations of biotin on the expression of macrophage IL-1β mRNA under LPS stimulation. FIG. 2, wherein FIG. 2A is a representative image of HE staining of lung tissue of mice in the blank control group, the IRI group and the Biotin intervention IRI group, FIG. 2B is a quantitative statistical graph of lung tissue inflammation scores, and FIG. 2C is a statistical graph of wet weight/dry weight ratio of lung tissue of mice in the IRI group and the Biotin intervention IRI group. Detailed Description The invention is further described below with reference to the drawings and specific examples, which are not intended to be limiting. It should be noted that, without conflict, the embodiments of the present invention and features of the embodiments may be combined with each other. The experimental methods, in which specific conditions are not noted in the following examples, are generally conducted under conventional conditions or under conditions recommended by the manufacturer. The reagents and materials used in the following examples are commercially available unless otherwise specified. EXAMPLE 1 inhibition of macrophage inflammatory response by biotin 1. Experimental method 1.1 Cell treatment The primary macrophages in the abdominal cavity of the mice are pretreated for 1 hour with biotin (also called vitamin H and coenzyme R, which are water-soluble vitamins) with different concentrations (0, 0.1, 1, 2 and 5 mM), and then lipopolysaccharide (LPS, 100 ng/mL) is added for stimulation for 4 hours to induce inflammatory response of the macrophages. 1.2 Gene expression analysis RNA extraction Total RNA from cells was extracted using TRIzol method, OD260/280 ratio was determined to ensure purity (1